首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1383659

無針糖尿病護理市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按設備類型、最終用戶、地區、競爭預測和機會細分，2018-2028 年

Needle Free Diabetes Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Device Type, By End User, By Region, By Competition Forecast & Opportunities, 2018-2028F

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 171 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2022 年全球無針糖尿病護理市場價值為 135.1 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年複合CAGR為15.49%。全球無針糖尿病護理市場是指醫療保健行業的細分市場該公司專注於提供傳統胰島素注射方法的替代方法來治療糖尿病。

市場規模及預測
- 按價值
市佔率及預測
- 依設備類型（胰島素輸注器、胰島素貼片、胰島素筆、胰島素幫浦、噴射注射器）
- 按最終使用者（家庭護理、診斷中心、醫院和診所）
- 按地區
- 按公司分類 (2022)
產品市場地圖
- 依設備類型
- 按最終用戶
- 按地區

第 6 章：北美無針糖尿病照護市場前景

市場規模及預測
- 按價值
市佔率及預測
- 依設備類型（胰島素輸注器、胰島素貼片、胰島素筆、胰島素幫浦、噴射注射器）
- 按最終使用者（家庭護理、診斷中心、醫院和診所）
- 按國家/地區
北美：國家分析
- 美國
- 加拿大
- 墨西哥

第 7 章：歐洲無針糖尿病護理市場前景

市場規模及預測
- 按價值
市佔率及預測
- 依設備類型（胰島素輸注器、胰島素貼片、胰島素筆、胰島素幫浦、噴射注射器）
- 按最終使用者（家庭護理、診斷中心、醫院和診所）
- 按國家/地區
歐洲：國家分析
- 德國
- 英國
- 法國
- 義大利
- 西班牙

第 8 章：亞太地區無針糖尿病護理市場展望

市場規模及預測
- 按價值
市佔率及預測
- 依設備類型（胰島素輸注器、胰島素貼片、胰島素筆、胰島素幫浦、噴射注射器）
- 按最終使用者（家庭護理、診斷中心、醫院和診所）
- 按國家/地區
亞太地區：國家分析
- 中國
- 日本
- 印度
- 澳洲
- 韓國

第 9 章：南美洲無針糖尿病照護市場前景

市場規模及預測
- 按價值
市佔率及預測
- 依設備類型（胰島素輸注器、胰島素貼片、胰島素筆、胰島素幫浦、噴射注射器）
- 按最終使用者（家庭護理、診斷中心、醫院和診所）
- 按國家/地區
南美洲：國家分析
- 巴西
- 阿根廷
- 哥倫比亞

第 10 章：中東和非洲無針糖尿病護理市場前景

市場規模及預測
- 按價值
市佔率及預測
- 依設備類型（胰島素輸注器、胰島素貼片、胰島素筆、胰島素幫浦、噴射注射器）
- 按最終使用者（家庭護理、診斷中心、醫院和診所）
- 按國家/地區
MEA：國家分析
- 南非無針糖尿病護理
- 沙烏地阿拉伯無針糖尿病護理
- 阿拉伯聯合大公國無針糖尿病護理
- 科威特無針糖尿病護理

第 11 章：市場動態

促進要素
挑戰

第 12 章：市場趨勢與發展

近期發展
併購
產品發布

第 13 章：波特的五力分析

產業競爭
新進入者的潛力
供應商的力量
客戶的力量
替代產品的威脅

第14章：競爭格局

商業概覽
產品供應
最近的發展
財務（據報導）
主要人員
SWOT分析
- 3M Co
- Bioject Medical Technologies Inc
- Valeritas Inc
- Antares Pharma Inc
- Endo International PLC
- InsuJet
- Pharmajet Inc
- INJEX Pharma AG
- Johnson & Johnson
- MannKind Corp

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄

Product Code: 18811

Global Needle Free Diabetes Care Market has valued at USD 13.51 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 15.49% through 2028. The global needle-free diabetes care market refers to the segment of the healthcare industry that focuses on providing alternatives to traditional insulin injection methods for managing diabetes.

Key Market Drivers

Rising Diabetes Prevalence

The steady rise in diabetes prevalence is often attributed to factors such as sedentary lifestyles, poor dietary choices, and an aging population. The burden of diabetes extends beyond individual health, straining healthcare systems and economies. This pressing global health issue has necessitated the development of more efficient and accessible methods for diabetes management.

Diabetes management has transitioned from a physician-driven approach to one that is increasingly patient-centric. Patients seek solutions that offer convenience, reduce pain, and enhance their overall quality of life. Traditional insulin injections, with their associated discomfort and inconvenience, are losing favor among individuals with diabetes. This shift in patient preferences has paved the way for the adoption of needle-free alternatives.

Advancements in medical technology have led to the creation of innovative needle-free diabetes care solutions. Insulin pumps, for instance, provide a consistent insulin supply throughout the day, minimizing the need for multiple injections and enhancing glucose control. Continuous glucose monitoring systems (CGMs) offer real-time data, empowering individuals to make informed decisions about insulin dosages and lifestyle adjustments. These technological breakthroughs align perfectly with the desire for patient-friendly diabetes management options.

Adherence to prescribed insulin therapy is a critical factor in diabetes management. Needle-free options often boast higher adherence rates as they are less intimidating and more convenient. Reduced pain and discomfort associated with injections can lead to improved treatment compliance, resulting in better glycemic control and health outcomes.

Increased awareness of diabetes and the availability of innovative treatment options have contributed to their adoption. Healthcare organizations, providers, and pharmaceutical companies are actively engaged in educating both patients and healthcare professionals about the benefits of needle-free solutions. This awareness-building effort has fostered the acceptance and utilization of these technologies.

Regulatory agencies are streamlining the approval process for needle-free diabetes care devices, making it easier for manufacturers to bring their products to market. This regulatory support has encouraged investment and innovation in the field, further propelling market growth.

Patient-Centric Care

Patient-centric care represents a paradigm shift in healthcare, emphasizing the importance of actively involving patients in their treatment decisions. It recognizes that patients are more than just recipients of medical care; they are partners in their healthcare journey. As this approach gains traction, it has reshaped the diabetes management landscape, focusing on enhancing the overall patient experience.

Traditional insulin injections, which involve needles and syringes, are often viewed as daunting and uncomfortable by individuals with diabetes. Patient-centric care acknowledges these concerns and strives to address them. This is where needle-free diabetes care solutions come into play. These technologies, such as insulin pumps and continuous glucose monitoring systems (CGMs), align with patient preferences for less painful and more convenient options.

One of the key advantages of needle-free diabetes care is the reduced pain and discomfort associated with insulin injections. Patients are more likely to adhere to their treatment regimens when they have access to less intimidating options. This improved adherence can lead to better glycemic control and overall health outcomes.

Patient-centric care seeks to improve the overall quality of life for individuals living with diabetes. Needle-free solutions offer greater flexibility and convenience, allowing patients to go about their daily activities without the burden of frequent injections. For many, this translates into a better sense of normalcy and improved emotional well-being.

Patient engagement and empowerment are key elements of patient-centric care. Needle-free technologies like CGMs empower individuals with diabetes by providing real-time data on their glucose levels. This information enables patients to make informed decisions about insulin dosages and lifestyle choices, putting them in control of their health.

Patient-centric care fosters stronger patient-provider relationships based on trust and collaboration. Healthcare professionals are more likely to recommend and prescribe needle-free diabetes care options when they know that these solutions align with their patients' preferences and needs.

Technological Advancements

Over the years, diabetes care has witnessed a remarkable evolution, thanks to rapid technological advancements. These innovations are making diabetes management more efficient, precise, and patient-friendly. Traditional insulin injections, while effective, have limitations that are being increasingly addressed by new technologies.

One of the key technological advancements in diabetes care is the development of insulin pumps. These devices provide a continuous supply of insulin throughout the day, eliminating the need for multiple injections. Insulin pumps offer precise control over glucose levels, helping individuals achieve better glycemic control. This technology aligns with the trend towards personalized medicine, allowing for customized insulin delivery.

Continuous glucose monitoring systems (CGMs) represent another milestone in diabetes care. These devices track glucose levels in real-time, providing valuable data that empowers individuals with diabetes to make informed decisions about their insulin dosages and lifestyle choices. CGMs are non-invasive and offer convenience and accuracy that traditional fingerstick testing cannot match.

Inhalable insulin, delivered through devices like inhalers, is another noteworthy advancement in diabetes care. This method offers a needle-free alternative for delivering insulin, making it more appealing to those who are averse to injections. Inhalable insulin provides rapid onset, reducing the waiting time for insulin to take effect.

Technological advancements have also led to greater connectivity and data integration in diabetes management. Mobile apps, wearable devices, and cloud-based platforms allow patients and healthcare providers to access and analyze glucose data remotely. This foster improved communication, better care coordination, and timely adjustments to treatment plans.

AI and predictive analytics are making inroads into diabetes care. These technologies can analyze vast datasets to predict glucose trends and provide personalized recommendations for insulin dosages and dietary choices. This proactive approach to diabetes management can help prevent hypoglycemic and hyperglycemic events.

Regulatory bodies have recognized the potential of these technologies and are streamlining the approval process for needle-free diabetes care devices. This regulatory support, combined with significant investments by healthcare companies and startups, is driving the development and commercialization of these innovations.

Improved Adherence

Adherence to insulin therapy and glucose monitoring is a significant challenge in diabetes management. Traditional insulin injections, which involve needles and syringes, can be painful and intimidating for many patients. This discomfort often leads to avoidance of insulin administration, missed doses, and suboptimal glycemic control. Needle-related anxiety and fear of pain are well-documented barriers to adherence.

The advent of needle-free diabetes care solutions has revolutionized diabetes management by providing alternatives to painful injections. Devices such as insulin pumps and continuous glucose monitoring systems (CGMs) reduce or eliminate the need for needles, making diabetes care more patient centric. This shift has a profound impact on adherence rates.

Needle-free solutions are designed to minimize discomfort during diabetes management. Insulin pumps, for instance, deliver insulin continuously, reducing the need for multiple injections. CGMs offer real-time glucose monitoring without fingerstick tests. The reduced pain and inconvenience associated with these technologies encourage individuals to adhere to their prescribed treatment regimens.

Convenience plays a vital role in adherence. Needle-free solutions offer greater convenience as they require fewer steps, less preparation time, and fewer supplies compared to traditional injections. Insulin pumps can be worn discreetly, and CGMs provide continuous data without the need for manual glucose checks. This convenience factor encourages individuals to stick to their diabetes management routines.

Better adherence leads to improved glycemic control, reducing the risk of diabetes-related complications such as heart disease, kidney damage, and neuropathy. Needle-free solutions not only make it easier for patients to manage their diabetes but also contribute to better long-term health outcomes.

Needle-free solutions are often accompanied by education and training programs that empower patients to take control of their diabetes care. Patients who understand how to use these devices effectively are more likely to adhere to their treatment plans and achieve better outcomes.

Improved adherence with needle-free solutions can have psychological benefits as well. Patients experience less anxiety and fear associated with needles, reducing the mental and emotional burden of diabetes management. This, in turn, positively impacts their overall well-being.

Key Market Challenges

Regulatory Approvals

One of the primary challenges facing the needle-free diabetes care market is obtaining regulatory approvals for new devices and technologies. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have stringent requirements for safety and efficacy. Navigating the regulatory landscape can be time-consuming and expensive for manufacturers, delaying product launches.

Patient Acceptance

While needle-free solutions offer numerous advantages, patient acceptance and adoption can be a challenge. Many individuals with diabetes are accustomed to traditional insulin injections and may be hesitant to switch to new technologies. Overcoming needle-related anxiety and educating patients about the benefits of needle-free options is crucial for market growth.

Technical Challenges

Developing and manufacturing needle-free devices with the required precision and reliability is technically challenging. These devices must deliver insulin accurately, maintain safety standards, and be user-friendly. Achieving these goals while keeping production costs reasonable is a significant technical hurdle.

Key Market Trends

Closed-Loop Systems

Closed-loop insulin delivery systems, often referred to as artificial pancreases, are gaining momentum. These systems automatically adjust insulin delivery in response to CGM data, offering individuals with diabetes better control over their blood glucose levels. As technology matures, it is likely to become more accessible and user-friendly.

Artificial Intelligence (AI) Integration

AI is poised to revolutionize diabetes care by offering personalized treatment recommendations based on real-time data. AI-powered algorithms can analyze continuous glucose monitoring (CGM) data and insulin delivery patterns to provide tailored insulin dosage suggestions. These AI-driven insights can improve glycemic control and reduce the risk of hypoglycemic events.

IoT and Wearable Devices

The Internet of Things (IoT) is influencing diabetes care through wearable devices. Smartwatches and continuous glucose monitors can sync with mobile apps, providing users with real-time insights into their health. These devices enhance patient engagement and offer healthcare providers a more comprehensive view of patient data.

Segmental Insights

Device Type Insights

Based on the category of Device Type, Insulin pumps are poised to dominate the Global Needle-Free Diabetes Care Market in 2022 due to their compelling advantages over traditional insulin injection methods. These cutting-edge devices offer precise and continuous insulin delivery, allowing for better blood glucose control and improved quality of life for diabetes patients. The convenience of needle-free administration not only reduces the pain associated with injections but also eliminates the need for multiple daily injections, leading to increased patient compliance. Moreover, insulin pumps enable healthcare professionals to remotely monitor and adjust insulin dosages, providing personalized care and reducing the risk of complications. As technology continues to advance, insulin pumps are expected to integrate even more sophisticated features, further solidifying their position as the preferred choice in diabetes management, thus driving their dominance in the global market.

End User Insights

The domination of the Global Needle-Free Diabetes Care Market in 2022 by homecare solutions is imminent, driven by several compelling factors. Firstly, the increasing preference for patient-centered care and the convenience of managing diabetes from the comfort of one's home are undeniable advantages. Homecare needle-free devices empower individuals to take charge of their diabetes management, reducing the need for frequent visits to healthcare facilities. Additionally, these devices offer greater flexibility and autonomy, allowing patients to tailor their treatment plans to suit their lifestyles and schedules. The ongoing advancements in technology have led to the development of user-friendly, compact, and affordable homecare options, further facilitating their adoption. With the growing global burden of diabetes, the accessibility and cost-effectiveness of homecare solutions make them poised for dominance in the market, promising a brighter and more convenient future for diabetes management.

Regional Insights

North America is positioned to dominate the Global Needle-Free Diabetes Care Market in 2022 for several compelling reasons. Firstly, the region boasts a well-established healthcare infrastructure and a high prevalence of diabetes, which drives demand for advanced diabetes management solutions. Moreover, the North American market benefits from robust research and development activities, fostering innovation in needle-free diabetes care technology. Additionally, favorable reimbursement policies and a strong focus on patient-centric healthcare contribute to the rapid adoption of these advanced devices. Furthermore, a proactive regulatory environment ensures that new needle-free diabetes care products can swiftly enter the market, positioning North America as a hub for innovation and market leadership in this sector. With a combination of high demand, innovative capabilities, and supportive healthcare policies, North America is poised to maintain its dominance in the Global Needle-Free Diabetes Care Market.

Key Market Players

3M Co

Bioject Medical Technologies Inc

Valeritas Inc

Antares Pharma Inc

Endo International PLC

InsuJet

Pharmajet Inc

INJEX Pharma AG

Johnson & Johnson

MannKind Corp

Report Scope:

In this report, the Global Needle Free Diabetes Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Needle Free Diabetes Care Market, By Device Type:

Insulin Infuser
Insulin Patches
Insulin Pens
Insulin Pumps
Jet Injectors

Needle Free Diabetes Care Market, By End User:

Homecare
Diagnostic Center
Hospitals & Clinic

Needle Free Diabetes Care Market, By Region:

North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Asia-Pacific
China
Japan
India
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Needle Free Diabetes Care Market.

Available Customizations:

Global Needle Free Diabetes Care market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Needle Free Diabetes Care Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Device Type (Insulin Infuser, Insulin Patches, Insulin Pens, Insulin Pumps, Jet Injectors)
- 5.2.2. By End User (Homecare, Diagnostic Center, Hospitals & Clinic)
- 5.2.3. By Region
- 5.2.4. By Company (2022)
5.3. Product Market Map
- 5.3.1. By Device Type
- 5.3.2. By End User
- 5.3.3. By Region

6. North America Needle Free Diabetes Care Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Device Type (Insulin Infuser, Insulin Patches, Insulin Pens, Insulin Pumps, Jet Injectors)
- 6.2.2. By End User (Homecare, Diagnostic Center, Hospitals & Clinic)
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Needle Free Diabetes Care Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Device Type
    - 6.3.1.2.2. By End User
- 6.3.2. Canada Needle Free Diabetes Care Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Device Type
    - 6.3.2.2.2. By End User
- 6.3.3. Mexico Needle Free Diabetes Care Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Device Type
    - 6.3.3.2.2. By End User

7. Europe Needle Free Diabetes Care Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Device Type (Insulin Infuser, Insulin Patches, Insulin Pens, Insulin Pumps, Jet Injectors)
- 7.2.2. By End User (Homecare, Diagnostic Center, Hospitals & Clinic)
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Needle Free Diabetes Care Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Device Type
    - 7.3.1.2.2. By End User
- 7.3.2. United Kingdom Needle Free Diabetes Care Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Device Type
    - 7.3.2.2.2. By End User
- 7.3.3. France Needle Free Diabetes Care Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Device Type
    - 7.3.3.2.2. By End User
- 7.3.4. Italy Needle Free Diabetes Care Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Device Type
    - 7.3.4.2.2. By End User
- 7.3.5. Spain Needle Free Diabetes Care Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Device Type
    - 7.3.5.2.2. By End User

8. Asia-Pacific Needle Free Diabetes Care Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Device Type (Insulin Infuser, Insulin Patches, Insulin Pens, Insulin Pumps, Jet Injectors)
- 8.2.2. By End User (Homecare, Diagnostic Center, Hospitals & Clinic)
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Needle Free Diabetes Care Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Device Type
    - 8.3.1.2.2. By End User
- 8.3.2. Japan Needle Free Diabetes Care Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Device Type
    - 8.3.2.2.2. By End User
- 8.3.3. India Needle Free Diabetes Care Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Device Type
    - 8.3.3.2.2. By End User
- 8.3.4. Australia Needle Free Diabetes Care Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Device Type
    - 8.3.4.2.2. By End User
- 8.3.5. South Korea Needle Free Diabetes Care Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Device Type
    - 8.3.5.2.2. By End User

9. South America Needle Free Diabetes Care Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Device Type (Insulin Infuser, Insulin Patches, Insulin Pens, Insulin Pumps, Jet Injectors)
- 9.2.2. By End User (Homecare, Diagnostic Center, Hospitals & Clinic)
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Needle Free Diabetes Care Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Device Type
    - 9.3.1.2.2. By End User
- 9.3.2. Argentina Needle Free Diabetes Care Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Device Type
    - 9.3.2.2.2. By End User
- 9.3.3. Colombia Needle Free Diabetes Care Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Device Type
    - 9.3.3.2.2. By End User

10. Middle East and Africa Needle Free Diabetes Care Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Device Type (Insulin Infuser, Insulin Patches, Insulin Pens, Insulin Pumps, Jet Injectors)
- 10.2.2. By End User (Homecare, Diagnostic Center, Hospitals & Clinic)
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Needle Free Diabetes Care Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Device Type
    - 10.3.1.2.2. By End User
- 10.3.2. Saudi Arabia Needle Free Diabetes Care Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Device Type
    - 10.3.2.2.2. By End User
- 10.3.3. UAE Needle Free Diabetes Care Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Device Type
    - 10.3.3.2.2. By End User
- 10.3.4. Kuwait Needle Free Diabetes Care Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Device Type
    - 10.3.4.2.2. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (As Reported)
14.5. Key Personnel
14.6. SWOT Analysis
- 14.6.1. 3M Co
- 14.6.2. Bioject Medical Technologies Inc
- 14.6.3. Valeritas Inc
- 14.6.4. Antares Pharma Inc
- 14.6.5. Endo International PLC
- 14.6.6. InsuJet
- 14.6.7. Pharmajet Inc
- 14.6.8. INJEX Pharma AG
- 14.6.9. Johnson & Johnson
- 14.6.10. MannKind Corp